###begin article-title 0
Kallmann Syndrome: Mutations in the Genes Encoding Prokineticin-2 and Prokineticin Receptor-2
###end article-title 0
###begin p 1
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1</italic>
###xml 584 592 584 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PROKR2)</italic>
###xml 632 640 632 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PROK2),</italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 727 733 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 872 878 872 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 929 934 929 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1,</italic>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
###xml 1174 1177 <span type="species:ncbi:9606">man</span>
Kallmann syndrome combines anosmia, related to defective olfactory bulb morphogenesis, and hypogonadism due to gonadotropin-releasing hormone deficiency. Loss-of-function mutations in KAL1 and FGFR1 underlie the X chromosome-linked form and an autosomal dominant form of the disease, respectively. Mutations in these genes, however, only account for approximately 20% of all Kallmann syndrome cases. In a cohort of 192 patients we took a candidate gene strategy and identified ten and four different point mutations in the genes encoding the G protein-coupled prokineticin receptor-2 (PROKR2) and one of its ligands, prokineticin-2 (PROK2), respectively. The mutations in PROK2 were detected in the heterozygous state, whereas PROKR2 mutations were found in the heterozygous, homozygous, or compound heterozygous state. In addition, one of the patients heterozygous for a PROKR2 mutation was also carrying a missense mutation in KAL1, thus indicating a possible digenic inheritance of the disease in this individual. These findings reveal that insufficient prokineticin-signaling through PROKR2 leads to abnormal development of the olfactory system and reproductive axis in man. They also shed new light on the complex genetic transmission of Kallmann syndrome.
###end p 1
###begin title 2
Synopsis
###end title 2
###begin p 3
###xml 906 910 906 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 915 921 915 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1,</italic>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
###xml 1050 1058 <span type="species:ncbi:9606">patients</span>
Kallmann syndrome is a developmental disease that affects both the hormonal reproductive axis and the sense of smell. In addition, various nonreproductive and nonolfactory anomalies are occasionally observed in a fraction of the patients. There is a developmental link between the reproductive and olfactory disorders: neuroendocrine cells producing the gonadotropin-releasing hormone that is deficient in the patients normally migrate from the nose to the forebrain along olfactory nerve fibers during embryonic life, and they most probably fail to do so in the patients. Affected individuals usually do not undergo spontaneous puberty. Hormone replacement therapy is the treatment to initiate virilization in males or breast development in females, and later, to develop fertility in both sexes. This is a hereditary disease with complex genetic transmission. Mutations in either of two different genes, KAL1 and FGFR1, have been found in approximately 20% of the affected individuals. The authors report on the identification (in a further 10% of patients) of various mutations in the prokineticin receptor-2 or prokineticin-2 genes, encoding a cell surface receptor and one of its ligands, respectively. Notably, some of the mutations were also detected in clinically unaffected individuals. This clearly indicates that additional, still unknown genetic or non-genetic factors are involved in disease production.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b001">1</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b002">2</xref>
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b003">3</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b004">4</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b005">5</xref>
###xml 707 708 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b006">6</xref>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
Kallmann syndrome (KS) combines hypogonadotropic hypogonadism and anosmia or hyposmia, i.e., a deficiency of the sense of smell [1]. Anosmia/hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts [2]. Hypogonadism is due to deficiency in gonadotropin-releasing hormone [3] and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons [4]. These cells normally migrate from the olfactory epithelium to the forebrain along the olfactory nerve pathway [5]. In some KS patients other developmental anomalies can be present, which include renal agenesis, cleft lip and/or palate, selective tooth agenesis, and bimanual synkinesis [6].
###end p 5
###begin p 6
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b007">7</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b009">9</xref>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1</italic>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b010">10</xref>
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b011">11</xref>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b006">6</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b012">12</xref>
###xml 629 630 629 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b006">6</xref>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
This is a genetically heterogeneous disease, which affects 1:8000 males and approximately five times less females. Two different genes have so far been identified. Loss-of-function mutations in KAL1 (NCBI GeneID: 3730) [7-9] and FGFR1 (NCBI GeneID: 2260) [10] account for the X-chromosome linked form and an autosomal dominant form of the disease, respectively. KAL1 encodes anosmin-1, a locally restricted glycoprotein of embryonic extracellular matrices [11], which is likely to be involved in fibroblast growth factor-signaling [6,12]. Nearly 80% of the KS patients, however, do not carry a mutation in either of these genes [6].
###end p 6
###begin p 7
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b007">7</xref>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b008">8</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b010">10</xref>
Because the common infertility in affected individuals and, most importantly, the incomplete penetrance of the disease impede linkage analysis, the positional cloning strategies that have been taken to find causative genes were based on the analysis of rare KS individuals who carry chromosomal rearrangements detectable by cytogenetics techniques [7,8,10]. Here, we used a direct candidate gene approach and identified two novel genes underlying the disease.
###end p 7
###begin title 8
Results/Discussion
###end title 8
###begin p 9
###xml 20 34 20 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GPR73L1/PROKR2</italic>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b013">13</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b015">15</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b016">16</xref>
###xml 473 479 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 576 577 576 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</bold>
###xml 856 865 856 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0020175-sg001">Figure S1</xref>
###xml 867 874 867 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0020175-t001">Table 1</xref>
###xml 880 888 880 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0020175-g001">Figure 1</xref>
###xml 989 998 989 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0020175-sg002">Figure S2</xref>
###xml 1677 1683 1677 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prokr2</italic>
###xml 1739 1745 1739 1745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 1918 1919 1918 1919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 942 948 <span type="species:ncbi:9913">bovine</span>
###xml 950 956 <span type="species:ncbi:10090">murine</span>
###xml 962 965 <span type="species:ncbi:10116">rat</span>
###xml 1320 1328 <span type="species:ncbi:9606">patients</span>
###xml 1693 1697 <span type="species:ncbi:10090">mice</span>
###xml 1817 1825 <span type="species:ncbi:9606">patients</span>
We first considered GPR73L1/PROKR2 (NCBI GeneID: 128674), encoding the prokineticin receptor-2 (PROKR2) [13-15], a most relevant candidate because olfactory bulbs do not develop normally in mutant mice lacking this G protein-coupled transmembrane receptor, and these mice also have a severe atrophia of the reproductive system related to the absence of gonadotropin-releasing hormone-synthesizing neurons in the hypothalamus [16]. We thus sequenced the two coding exons of PROKR2 and flanking splice sites in 192 unrelated individuals (144 males and 48 females) affected by KS, including 38 familial cases. Ten different mutations (one frameshift and nine missense mutations) were detected in 14 patients (four familial and ten apparently sporadic cases) in the heterozygous (ten cases), homozygous (two cases), or compound heterozygous (two cases) state (Figure S1, Table 1, and Figure 1). Conservation of the mutated amino acid residues in bovine, murine, and rat orthologous sequences (Figure S2) argues in favor of a deleterious effect for all the missense mutations. However, two of these mutations, p.R268C and p.V331M, as well as a mutation (c.253C>T, p.R85C) affecting the same residue as the p.R85H mutation found in two KS cases and another missense mutation (c.1004C>G, p.T335M) not found in the cohort of KS patients, were detected, once each, in 500 alleles from ethnically matched (Caucasian) control individuals. No other nonsynonymous variant was found in the controls. In the absence of functional testing, one cannot be sure that each missense mutation found in KS individuals is causative of the disease. Nevertheless, together with the KS-like phenotype of Prokr2 knockout mice, the fact that the overall proportion of PROKR2 alleles carrying nonsynonymous mutations is significantly higher in KS patients (18 out of 384 alleles) than in controls (four out of 500 alleles; chi-square value = 13.5, p < 0.001) strongly argues in favor of the involvement of the gene in KS.
###end p 9
###begin p 10
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b017">17</xref>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b018">18</xref>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b019">19</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b020">20</xref>
###xml 706 715 706 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0020175-sg001">Figure S1</xref>
###xml 717 724 717 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0020175-t001">Table 1</xref>
###xml 730 738 730 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0020175-g001">Figure 1</xref>
###xml 969 978 969 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0020175-sg002">Figure S2</xref>
###xml 1127 1129 1127 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b021">21</xref>
###xml 1265 1267 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b019">19</xref>
###xml 1268 1270 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b021">21</xref>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
Prokineticin-2 (PROK2) [17] is the main ligand of PROKR2. We considered the possibility that mutations in PROK2 (NCBI GeneID: 60675), account for some KS cases, especially since mutant mice defective in Prok2 have a marked reduction in the size of olfactory bulbs and a loss of their normal architecture [18]. We sequenced the four PROK2 coding exons (including the alternative exon 3 [19]) and flanking splice sites in the same cohort of patients and found four different point mutations (two missense mutations, one frameshift mutation, and one single nucleotide substitution in the translation initiation sequence [20]), all in the heterozygous state, in two familial and two apparently sporadic cases (Figure S1, Table 1, and Figure 1). These mutations were not detected, or any other sequence variant, in 500 alleles from ethnically matched (Caucasian) control individuals. The p.G32R mutation affects the glycine residue of the N-terminal hexapeptide AVITGA (see Figure S2). This motif, which is conserved among prokineticins from mammalian and non-mammalian species, is critical for the bioactivities of these proteins [21]. The p.R73C mutation introduces a cysteine residue, which is expected to disrupt the formation of the disulfide bonds of the protein [19,21].
###end p 10
###begin p 11
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b013">13</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b014">14</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b022">22</xref>
###xml 580 584 580 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b012">12</xref>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b023">23</xref>
###xml 942 944 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b025">25</xref>
###xml 1049 1051 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b016">16</xref>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b018">18</xref>
###xml 1055 1057 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b026">26</xref>
###xml 1162 1164 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b010">10</xref>
###xml 1386 1390 1386 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kal1</italic>
###xml 1426 1428 1426 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b027">27</xref>
###xml 1429 1431 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b028">28</xref>
###xml 1452 1456 1452 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 972 977 <span type="species:ncbi:10090">mouse</span>
###xml 1153 1159 <span type="species:ncbi:9606">humans</span>
###xml 1368 1373 <span type="species:ncbi:10090">mouse</span>
###xml 1379 1385 <span type="species:ncbi:10090">murine</span>
###xml 1446 1451 <span type="species:ncbi:9606">human</span>
###xml 1508 1513 <span type="species:ncbi:10090">mouse</span>
Considering both the phenotypes of the Prokr2- or Prok2-deficient mice and the likely deleterious effect of the human frameshift mutations on protein synthesis, the various PROKR2 and PROK2 missense mutations underlying KS are predicted to be loss-of-function mutations too. Since the same developmental disease, namely KS, apparently results from insufficient signaling either through FGFR1 or through PROKR2, the two signaling pathways are expected to interfere at some level, possibly the activation of the mitogen-activated protein kinase pathway [13,14,22]. In addition, the KAL1 gene product anosmin-1, which has been reported to enhance fibroblast growth-factor-signaling through FGFR1 [12], could also play a role in prokineticin-signaling through PROKR2. Indeed, both anosmin-1 and PROK2 have binding affinities for heparan sulfate glycosaminoglycans, which are also well known co-receptors in fibroblast growth-factor-signaling [23-25]. Notably, only homozygous mouse mutants lacking Prokr2, Prok2, or Fgfr1 show abnormal olfactory bulbs [16,18,26], whereas it seems that heterozygous mutations in any of the orthologous genes can cause KS in humans ([10] and this study). A unifying explanation could be that the local amount of anosmin-1 exerts a critical dosage effect both on FGFR1 and PROKR2 receptor activation, hence a higher dose of anosmin-1 in the mouse (the murine Kal1 is expected to be pseudoautosomal [27,28], whereas the human KAL1 is X chromosome-linked) could protect heterozygous mouse mutants from the developmental failure.
###end p 11
###begin p 12
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 142 150 142 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0020175-g001">Figure 1</xref>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b029">29</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b031">31</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 420 427 <span type="species:ncbi:9606">patient</span>
It is noteworthy that KS patients who carry mutations in PROKR2 or PROK2 have variable degrees of olfactory and reproductive dysfunction (see Figure 1). In addition, they do not seem to have any of the occasional clinical anomalies that have been reported in the previously characterized genetic forms of the disease, namely bimanual synkinesis, renal agenesis, dental agenesis, and cleft lip or palate. However, the KS patient carrying the p.R73C mutation in PROK2 suffers from a severe sleep disorder and marked obesity, which might be related to the known circadian function of prokineticin-2 and its potential roles in sleep-wake regulation and ingestive behavior [29-31].
###end p 12
###begin p 13
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 378 385 378 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0020175-t001">Table 1</xref>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 592 597 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1</italic>
###xml 688 694 688 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 698 704 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2,</italic>
###xml 783 789 783 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 875 879 875 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 888 897 888 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0020175-sg003">Figure S3</xref>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b032">32</xref>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b033">33</xref>
###xml 1152 1153 1152 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b006">6</xref>
###xml 1247 1256 1247 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen-0020175-sg003">Figure S3</xref>
###xml 1337 1343 1337 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 1650 1656 1650 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 1660 1665 1660 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 1744 1764 1744 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1, FGFR1, PROKR2,</italic>
###xml 1769 1774 1769 1774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
###xml 733 741 <span type="species:ncbi:9606">patients</span>
###xml 1369 1376 <span type="species:ncbi:9606">patient</span>
###xml 1611 1619 <span type="species:ncbi:9606">patients</span>
###xml 1857 1865 <span type="species:ncbi:9606">patients</span>
In human monogenic disorders, genuine dominance, where heterozygotes and homozygotes have the same phenotype, is unusual. In particular, most dominant developmental diseases are far more severe in the homozygous state. Therefore, the finding of both heterozygous and homozygous (or compound heterozygous) KS patients for a given mutation in PROKR2 (e.g., p.R85H or p.L173R, see Table 1) is quite remarkable and raises the question of a possible digenic mode of inheritance in heterozygous patients. In our cohort, none of the patients carrying a mutation in PROKR2 was carrying a mutation in PROK2 too. We did not find a mutation in FGFR1 in any of the individuals carrying a mutation in PROKR2 or PROK2, either. However, one of the patients heterozygous for the p.L173R mutation in PROKR2 (sporadic case) also carried a previously undescribed missense mutation, p.S396L, in KAL1 exon 8 (Figure S3), which was not detected in 500 alleles from control individuals. According to the predicted structure of anosmin-1 [32,33], the mutation modifies the first amino acid residue of the linker between the second and third fibronectin-like type III repeats [6], a residue that is conserved among orthologous proteins from vertebrates and invertebrates (Figure S3). This mutation thus can be regarded as causative of the disease. Likewise, the PROKR2 mutation carried by this patient, L173R, which was found in six unrelated KS individuals and none of the controls, is most likely pathogenic too. To date, this is the only case of possible digenic inheritance reported in KS. It is quite possible, however, that other patients heterozygous for mutations in PROKR2 or PROK2 also carry a mutation in another, still unknown KS gene. Indeed, mutations in KAL1, FGFR1, PROKR2, and PROK2 together account for approximately 30% of all the KS cases in our large series of patients, which indicates that still other genes underlying the disease remain undiscovered.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 522 527 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 532 539 532 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2.</italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 736 742 736 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 832 836 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 841 846 841 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1</italic>
###xml 880 881 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b009">9</xref>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b010">10</xref>
###xml 1052 1058 1052 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 1194 1199 1194 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 1207 1211 1207 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 767 775 <span type="species:ncbi:9606">patients</span>
Written informed consent was obtained from all the individuals who participated in the study. Genomic DNA was obtained from peripheral blood samples or lymphoblastoid cell lines by using a standard phenol chloroform extraction procedure. The genomic DNA from 250 unrelated Caucasian individuals was used as a control (control individuals were not examined to look for Kallmann syndrome features). We used the ENSEMBL () and UCSC () genome databases to find the exon-intron structure and single nucleotide polymorphisms of PROK2 and PROKR2. We designed PCR primer sets for amplification of exons and exon-intron boundaries using PRIMER 3 software (). Sequences of the primers used to amplify and sequence the PROK2 four-coding exons and PROKR2 two-coding exons in the patients and controls are listed below. The primers used for the KAL1 and FGFR1 coding exons have been reported [9,10]. All identified mutations were confirmed on a second PCR product. The alleles from control individuals were analyzed either by direct sequencing of the PCR products (PROKR2 exons) or by using a denaturing high-performance liquid chromatography standard procedure followed by sequencing of abnormal products (PROK2 exons, KAL1 exon 8).
###end p 15
###begin p 16
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
PROK2 primers:
###end p 16
###begin p 17
PROK2_1F: 5'-GGCGGGGCTAGCCTTTAT-3'
###end p 17
###begin p 18
PROK2_1R: 5'-CCTCTAGCCTGCCCTTCAG-3'
###end p 18
###begin p 19
PROK2_2F: 5'-CCCACTTTCGAAAAATGAGAA-3'
###end p 19
###begin p 20
PROK2_2R: 5'-TGTTTGTCGAGCACGTTACC-3'
###end p 20
###begin p 21
PROK2_3F: 5'-GGCTTGGCTGTATCTTGCTC-3'
###end p 21
###begin p 22
PROK2_3R: 5'-TGGGGCTGAACTGATAGGAC-3'
###end p 22
###begin p 23
PROK2_4F: 5'-GGGTAGTTAACGCTCAGTAAACA-3'
###end p 23
###begin p 24
PROK2_4R: 5'-GAGCATTTCTTTCTGGCACA-3'
###end p 24
###begin p 25
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
PROKR2 primers:
###end p 25
###begin p 26
PROKR2_1F: 5'-GGCTCACTGACCCTGAAAGA-3'
###end p 26
###begin p 27
PROKR2_1R: 5'-TGTCAGCCTGTCAGAGCCTA-3'
###end p 27
###begin p 28
PROKR2_2F: 5'-GGATTCACTGTGCCACTGC-3'
###end p 28
###begin p 29
PROKR2_2R: 5'-CCATGCAGCCTATGAACTTG-3'
###end p 29
###begin title 30
Supporting Information
###end title 30
###begin title 31
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 114 122 <span type="species:ncbi:9606">Patients</span>
DNA Sequence Electrophoretograms for the Four PROK2 Mutations and Ten PROKR2 Mutations Found in Kallmann Syndrome Patients
###end title 31
###begin p 32
###xml 303 309 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 417 424 <span type="species:ncbi:9606">patient</span>
Normal sequences are shown on the top, mutated sequences at the bottom. Asterisks denote sequences from the non-coding DNA strand. Mutations are indicated by vertical arrows. All the mutations were found in the heterozygous or compound heterozygous state in Kallmann syndrome patients. In addition, two PROKR2 mutations, namely c.254G>A (p.R85H) and c.518T>G (p.L173R), were also found in the homozygous state in one patient each.
###end p 32
###begin p 33
(2.4 MB TIF)
###end p 33
###begin p 34
Click here for additional data file.
###end p 34
###begin title 35
###xml 54 57 <span type="species:ncbi:9606">Man</span>
###xml 59 62 <span type="species:ncbi:9913">Cow</span>
###xml 64 69 <span type="species:ncbi:10090">Mouse</span>
###xml 75 78 <span type="species:ncbi:10116">Rat</span>
Alignment of PROKR2 and PROK2 Amino Acid Sequences in Man, Cow, Mouse, and Rat (CLUSTALW)
###end title 35
###begin p 36
###xml 50 58 <span type="species:ncbi:9606">patients</span>
The missense mutations found in Kallmann syndrome patients are indicated by arrowheads. In the PROK2 sequence, the additional peptide encoded by exon 3 (alternative splicing) is underlined, and the N-terminal AVITGA motif that is critical for the bioactivity of the protein is highlighted in yellow.
###end p 36
###begin p 37
(91 KB PDF)
###end p 37
###begin p 38
Click here for additional data file.
###end p 38
###begin title 39
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1,</italic>
###xml 60 67 <span type="species:ncbi:9606">Patient</span>
DNA Sequence Electrophoretograms from the Kallmann Syndrome Patient Carrying Missense Mutations in PROKR2 and KAL1, and Interspecies Comparison of the Amino Acid Sequence of KAL1 (Anosmin-1) around the Mutated Residue
###end title 39
###begin p 40
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KAL1</italic>
###xml 123 130 <span type="species:ncbi:9606">patient</span>
Control electrophoretograms are shown on the top. The mutations in PROKR2 and KAL1 are indicated by vertical arrows on the patient's electrophoretograms (bottom).
###end p 40
###begin p 41
###xml 98 121 98 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Caenorhabditis elegans,</italic>
###xml 126 149 126 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 48 51 <span type="species:ncbi:9606">man</span>
###xml 53 56 <span type="species:ncbi:9913">cow</span>
###xml 58 65 <span type="species:ncbi:9031">chicken</span>
###xml 67 76 <span type="species:ncbi:7955">zebrafish</span>
###xml 98 120 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
###xml 126 149 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Alignment of the KAL1 amino acid sequences from man, cow, chicken, zebrafish (kal1.1 and kal1.2), Caenorhabditis elegans, and Drosophila melanogaster shows the conservation of the mutated residue (Ser396) in vertebrates and invertebrates (either serine or threonine), whereas most of the surrounding residues are more variable.
###end p 41
###begin p 42
(943 KB TIF)
###end p 42
###begin p 43
Click here for additional data file.
###end p 43
###begin p 44
###xml 17 25 <span type="species:ncbi:9606">patients</span>
We thank all the patients and family members who participated in this study. We are grateful to the Service de Sequencage de l'Institut Cochin for sequencing facilities.
###end p 44
###begin title 45
Abbreviations
###end title 45
###begin p 46
Kallmann syndrome
###end p 46
###begin p 47
prokineticin-2
###end p 47
###begin p 48
prokineticin receptor-2
###end p 48
###begin title 49
References
###end title 49
###begin article-title 50
The genetic aspects of primary eunuchoidism
###end article-title 50
###begin article-title 51
Median cranioencephalic dysraphias and olfactogenital dysplasia
###end article-title 51
###begin article-title 52
###xml 95 98 <span type="species:ncbi:9606">men</span>
Effect of purified luteinizing hormone releasing factor on normal and hypogonadotropic anosmic men
###end article-title 52
###begin article-title 53
Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome
###end article-title 53
###begin article-title 54
###xml 92 98 <span type="species:ncbi:9606">humans</span>
The origin and migration of LHRH neurons in mammals: A comparison between species including humans
###end article-title 54
###begin article-title 55
Mechanisms of disease: Insights into X-linked and autosomal-dominant Kallmann syndrome
###end article-title 55
###begin article-title 56
A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules
###end article-title 56
###begin article-title 57
The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules
###end article-title 57
###begin article-title 58
Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome
###end article-title 58
###begin article-title 59
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR1</italic>
FGFR1 loss-of-function mutations cause autosomal dominant Kallmann syndrome
###end article-title 59
###begin article-title 60
Anosmin-1 is a regionally restricted component of basement membranes and interstitial matrices during organogenesis: Implications for the developmental anomalies of X chromosome-linked Kallmann syndrome
###end article-title 60
###begin article-title 61
###xml 69 74 <span type="species:ncbi:9606">human</span>
Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism
###end article-title 61
###begin article-title 62
Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor
###end article-title 62
###begin article-title 63
Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors
###end article-title 63
###begin article-title 64
Molecular cloning and characterization of prokineticin receptors
###end article-title 64
###begin article-title 65
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2
###end article-title 65
###begin article-title 66
Identification of two prokineticin cDNAs: Recombinant proteins potently contract gastrointestinal smooth muscle
###end article-title 66
###begin article-title 67
Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling
###end article-title 67
###begin article-title 68
Identification and pharmacological characterization of prokineticin 2 beta as a selective ligand for prokineticin receptor 1
###end article-title 68
###begin article-title 69
Regulation of translation via mRNA structure in prokaryotes and eukaryotes
###end article-title 69
###begin article-title 70
Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists
###end article-title 70
###begin article-title 71
Cellular signaling by fibroblast growth factor receptors
###end article-title 71
###begin article-title 72
Initial characterization of anosmin-1, a putative extracellular matrix protein synthesized by definite neuronal cell populations in the central nervous system
###end article-title 72
###begin article-title 73
The endocrine-gland-derived VEGF homolog Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells
###end article-title 73
###begin article-title 74
Structural basis for fibroblast growth factor receptor activation
###end article-title 74
###begin article-title 75
FGF signaling through FGFR1 is required for olfactory bulb morphogenesis
###end article-title 75
###begin article-title 76
Structure of the X-linked Kallmann syndrome gene and its homologous pseudogene on the Y chromosome
###end article-title 76
###begin article-title 77
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Sts)</italic>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
Cloning and expression of the mouse pseudoautosomal steroid sulphatase gene (Sts)
###end article-title 77
###begin article-title 78
Prokineticin 2 transmits the behavioral circadian rhythm of the suprachiasmatic nucleus
###end article-title 78
###begin article-title 79
###xml 91 95 <span type="species:ncbi:10116">rats</span>
Bv8, the amphibian homolog of the mammalian prokineticins, modulates ingestive behavior in rats
###end article-title 79
###begin article-title 80
Prokineticin 2 and circadian clock output
###end article-title 80
###begin article-title 81
###xml 143 148 <span type="species:ncbi:9606">human</span>
Molecular modeling and experimental studies of mutation and cell-adhesion sites in the fibronectin type III and whey acidic protein domains of human anosmin-1
###end article-title 81
###begin article-title 82
Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation, and constrained modeling
###end article-title 82
###begin title 83
Figures and Tables
###end title 83
###begin title 84
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
Segregation of Kallmann Syndrome and the PROKR2 or PROK2 Mutations in Affected Families
###end title 84
###begin p 85
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0020175-b013">13</xref>
Filled symbols denote clinically affected individuals with both hypogonadism and anosmia (or hyposmia). Half-filled symbols denote individuals with either anosmia only (right black part) or hypogonadism only (left black part). Genotypes, if available, are indicated below. The symbol + denotes normal allele, and fs stands for frameshift mutation. In several pedigrees the mutation is associated with varying phenotypes. Notably, in family A the disease apparently segregates according to a semi-dominant mode of transmission. The schematic representation of PROKR2 shows the locations of the nine missense mutations found in familial and non-familial KS cases, with respect to the putative N-terminal (N ter), C-terminal (C ter), extracellular loop (e1-e3), intracellular loop (i1-i3), and transmembrane (T1-T7) domains [13] of this G protein-coupled receptor.
###end p 85
###begin p 86
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROKR2</italic>
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROK2</italic>
PROKR2 and PROK2 Mutations in Kallmann Syndrome
###end p 86
###begin p 87
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 87
###begin p 88
A previous version of this article appeared as an Early Online Release on August 31, 2006 (DOI: ).
###end p 88
###begin p 89
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. MD and CP supported the project. CD and JPH conceived and designed the experiments. CD, LT, and CF performed the experiments. CD and JPH analyzed the data. JL, PB, MLK, JL, ALR, MM, AM, GM, AM, JET, SW, and JY contributed reagents/materials/analysis tools. JPH wrote the paper.
###end p 89
###begin p 90
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported by grants from GIS-Maladies Rares 2002 (A02209JS) and Agence Nationale pour la Recherche (ANR-05-MRAR-027-01). LT was supported by a fellowship from the Fondation pour la Recherche Medicale.
###end p 90

